← Back to Clinical Trials
Recruiting NCT06968637

NCT06968637 Improving Patient-centered Care for Diabetes in Bangladesh Through "Dynamic Integration" of Vision Care on the Supply Side

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06968637
Status Recruiting
Phase
Sponsor Orbis
Condition Diabetes Mellitus
Study Type INTERVENTIONAL
Enrollment 336 participants
Start Date 2025-08-25
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
care recommendations

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 336 participants in total. It began in 2025-08-25 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to determine whether integration of vision care into the DM treatment system, by providing specific recommendations to doctors for management of diabetes alongside feedback on positive eye exams for DR can improve diabetes care outcomes. The main questions it aims to answer are: 1. Does delivery of specific diabetes management recommendations to diabetes doctors for patients of theirs found to have DR lead to significantly improved blood glucose control as indicated by % reaching WHO targets of HbA1c (or targets for blood sugar if HbA1c data are unavailable)? 2. What is the cost-effectiveness of the intervention, measured as total intervention cost per additional participant reaching the WHO target? Researchers will compare participant adherence with international guidelines when DR results are provided by a PIS without specific care recommendations to when the PIS provides DR results with specific care recommendations for DM management.

Eligibility Criteria

Inclusion Criteria: * Diagnosed with DM * Diagnosed with DR in at least one eye * Over 30 years of age * Currently treated at the Dinajpur Diabetes Hospital and Gausul Azam BNSB Eye Hospital in Bangladesh * willingness to participate in the study Exclusion Criteria: * Any ocular condition impairing the view of the fundus sufficiently to preclude grading of the image for DR. * Inability to comply with retinal photography to the extent that a gradable image cannot be captured, or any other factor leading to absence of sufficient images to grade at least one eye of a participant. * Medical conditions that could impair compliance with follow-up (such as stroke, dementia, etc.) * Unwilling to participate in the study, or incapable of giving informed consent.

Contact & Investigator

Central Contact

Lutful Husain

✉ lutful.husain@orbis.org

📞 +8801711626852

Principal Investigator

Munir Ahmed

PRINCIPAL INVESTIGATOR

Orbis Bangladesh

Frequently Asked Questions

Who can join the NCT06968637 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06968637 currently recruiting?

Yes, NCT06968637 is actively recruiting participants. Contact the research team at lutful.husain@orbis.org for enrollment information.

Where is the NCT06968637 trial being conducted?

This trial is being conducted at Dinajpur Sadar, Bangladesh, Dinajpur District, Bangladesh.

Who is sponsoring the NCT06968637 clinical trial?

NCT06968637 is sponsored by Orbis. The principal investigator is Munir Ahmed at Orbis Bangladesh. The trial plans to enroll 336 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology